Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Total body scans under identical conditions and using 18F and 99mTc-EHDP were carried out in patients with known, or subsequently proven, metastases. There was no statistical evidence for any difference in the number of scintigraphically demonstrable lesions. Patients with internal prostheses who developed infections of the prosthesis show no significant difference in the uptake of either nucleid. Soft tissue lesions showed a significantly higher uptake of 99mTc-EHDP than of 18F. 18F can be replaced for nearly all problems by 99mTc-EHDP without loss of diagnostic information.
 ...
PMID:[Comparative investigations concerning osteotropic radiopharmaceuticals. III. Scanning with 18F and 99mTc-malignant diseases (author's transl)]. 12 7

The early detection of metastatic spread in sixteen patients with osteosarcoma has been studied over a twelve month period, comparing the techniques of bone scanning and radiography. In only two patients were we able to demonstrate changes suggestive of pulmonary metastases any earlier with a 99mTc-EHDP scan than with chest radiographs and one of these resolved spontaneously. However, the bone scan did accurately delineate the extent of the primary tumour and may, therefore, be helpful in deciding the level of the amputation and the response of the patient to treatment, particularly now that chemotherapy and immunotherapy are frequently used in the management of the disease.
 ...
PMID:The use of 99mc-EHDP as a scanning agent in the detection of metastases from osteosarcoma. 14 18

We have compared bone scintigrams made with Tc-99m-tagged HEDP (1-hydroxyethylidene diphosphonate)and MDP (methylene diphosphonate), the former at 4 hr after injection, the latter at both 2 and 4 hr. In 17 patients with skeletal metastases, there was no significant difference in lesion count or scan quality between the 4-hr images. The tumor-to-bone ratio (T/B) was significantly higher with Tc-HEDP (p less than 0.02). Lesion detection rate and T/B ratios were both lower with Tc-MDP at 2 hr when compared with the 4-hr values for both Tc-HEDP (p less than 0.02, p less than 0.005) and Tc-MDP (p less than 0.02, p less than 0.01). The 4-hr Tc-MDP scan was of significantly higher quality than the 2 hr Tc-MDP scan (p less than 0.01). Although Tc-HEDP produces a higher T/B ratio at 4 hr, the present study does not suggest that either agent is superior in clinical practice.
 ...
PMID:A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication. 43 Feb 2

Following a firm diagnostic and therapeutic schedule for patients with prostatic carcinoma. 89Strontium therapy was introduced for multiple metastases. Positive skeletal scintigraphy with 99mTc-EHDP induced check for affinity to Sr using 85Sr scintigraphy. Of 80 patients, multiple metastases were found in 26. Therapy with 1 mCi of 89Sr-chloride was started in 20 cases. In 8 patients, relief from severe pain appeared shortly afterward, and a further 8 it was possible to prevent the development of pain. Moderate success in 3 cases and a failure to provide relief in 1 were observed.
 ...
PMID:89Strontium therapy of bone metastases of carcinoma of the prostatic gland. 49 25

Bone scanning with 99mTc-Sn-HEDP, radiographic skeletal survey and determination of plasma acid and alkaline phosphatase values were carried out in a consecutive series of 90 untreated patients with carcinoma of the prostate. 99mTc-Sn-HEDP provided satisfactory bone imaging and was convenient in use. The addition of bone scanning to radiographic survey increases the detection rate of skeletal metatases by 16%. Radiography increases the accuracy of bone scanning by identifying false positive scans due to benign disease and false negative scans when there are diffuse symmetrical bony metastases. The plasma phosphatases alone are less accurate staging tests. The acid phosphatase data support the validity of scan positive--X-ray negative findings. Bone scan abnormalities due to secondary deposits usually precede elevation of plasma alkaline phosphatase.
 ...
PMID:Bone scanning and plasma phosphatases in carcinoma of the prostate. 75 55

Single intravenous injections of 30 to 35 mCi (1,110 to 1,295 MBq) of Re-186(Sn)HEDP previously have been shown to result in palliation of painful skeletal metastases from prostate cancer. There are no reports of patients receiving repetitive Re-186(Sn)HEDP therapy. We have followed two such patients who received multiple (five to seven) injections of Re-186(Sn)HEDP at 2-month intervals. Each experienced a sustained decrease in both pain and analgesic intake. The only evident clinical or biochemical toxicity was a mild progressive decline in their total platelet counts.
 ...
PMID:Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. 137 56

The pharmacokinetics of 186Re-HEDP, a radiopharmaceutical for palliative treatment of metastatic bone pain, was investigated in 11 patients (17 studies) who suffered from metastatic breast or prostate cancer. Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40.1 +/- 5.0, 41.0 +/- 6.0 and 29.5 +/- 6.4 hr, respectively. Time-dependent increase in plasma-protein binding was observed, probably caused by in vivo decomposition of 186Re-HEDP. Total urinary 186Re excretion was 69% +/- 15%, of which 71% +/- 6% was excreted in the first 24 hr after injection. The BSI (i.e., fraction of the skeleton showing scintigraphic evidence of metastatic disease) closely correlated with the fraction of dose non-renally cleared (r = 0.98). This implies that the amount of radioactivity taken up by the skeleton and hence the bone marrow absorbed dose can be predicted from a diagnostic pre-therapy 99mTc-HDP scintigram. The pharmacokinetic behavior indicates that 186Re-HEDP has suitable properties to justify its application.
 ...
PMID:Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. 137 67

Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease. In these patients in whom high dose EHDP therapy has been instituted, uptake of the bone scan agent is markedly diminished. The case presented illustrates this finding: a breast cancer patient who had received two 500-mg intravenous doses of EHDP prior to bone scan staging. No skeletal visualization was present at 3 hr after 99mTc-MDP injection. Blood-pool activity and uptake in large metastatic sites were observed.
 ...
PMID:Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. 156 85

Bone scanning with 99mTc-EHDP or 99mTc-MDP was compared with skeletal X-ray survey, determination of acid phosphatase levels and clinical symptoms in a consecutive series of 176 patients with prostatic carcinoma. Skeletal metastases were present in 24%. In these metastatic cases 27% had negative radiographics at the time of initial diagnosis, 29% had normal serum acid phosphatase values and 74% had symptoms other than skeletal, which dominated the clinical picture. When bone scanning was negative for metastases such lesions were never detected in the radiographs. Hence, bone scanning was sufficient for the initial diagnosis of skeletal metastases in 55% of cases. When scans were judged as equivocal or positive an X-ray survey should be done. The variations in count density in metastatic disease were followed by visual assessment of serial bone scans. A densitometric method for quantification of the variations was developed as an aid in the evaluation. Serial bone scanning using a quantitative method appears to offer a readily available objective index of early therapeutic response for use in general clinical practice as well as in controlled therapeutic trails.
 ...
PMID:Serial bone scanning in the evaluation of stage and clinical course in carcinoma of the prostate. 693 33

Prostate carcinoma is the most commonly associated with osseous metastases malignancy in males. The lesions, being usually of a mixed sclerotic/lytic variety and less often of the pure sclerotic type, need to be treated by a bone seeking radioactive element with an as low as possible radiobiological burden on the surrounding (peritumoral) tissues. Rhenium-186-HEDP was used to treat these osseous metastatic lesions due to its bone seeking kinetics attractive radiochemical properties. Of a total of 16 prostate cancer patients. 3 experiment loss of pain, 8 experienced obvious and 2 some improvement. No change was observed in 3 patients. Ten patients manifested a flare syndrome increasing pain approximately 2 to 6 days, after Re-186-HEDP i.v. application. Six patients showed a definite and 9 a slight decrease in platelet levels and absolute number of polymorphonuclear white blood cells, up to fourth week following treatment. One patient underwent a whole blood transfusion and in 2 peripheral neuropathy was observed lasting about 9 to 12 days. Re-186-HEDP appears to be a promising new metal ion complex for the palliation of painful bone metastases in prostate cancer. Compared to Sr-89 therapy, it shows a longer analgetic efficacy and has the advantage of emitting gamma rays, a fact which facilitates dosimetric calculations.
 ...
PMID:Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. 917 22


1 2 3 Next >>